Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

All news Pharmasist News & insight

Premarin cream discontinued, tablets to follow: What are the alternatives?

Health Canada says some estrogen patch shortages may persist into early 2027 as Premarin cream and tablets leave Canada. CPhA’s November resource outlines hormonal, vaginal and nonhormonal alternatives.

7 min read7 sources
Share LinkedIn X Facebook Email
In this article & details

Article details

Published
Nov 17, 2026
Reading time
7 min read
Categories
Drug Access, Drug Shortages
Jurisdiction
National
Sources cited
7
All news

Health Canada’s November 19 shortage notice says interruptions affecting some estrogen patch strengths may continue into early 2027, alongside the withdrawal of Premarin cream and planned end of tablet sales. The department points to a Canadian Pharmacists Association resource outlining treatment alternatives.

CPhA’s November 2026 Menopausal Hormone Therapy Shortage resource covers systemic hormones, local vaginal treatments and nonhormonal medicines. It also addresses monitoring after a switch, endometrial protection and confirming coverage through public formularies or private insurance.

Pfizer’s Premarin withdrawal covers cream and all three tablet strengths

Pfizer confirmed to Reuters on Nov. 12 that it is ending Canadian sales of Premarin vaginal cream and all three strengths of its Premarin tablets. No more batches of the cream are planned. The company expects its remaining tablet stock to last until around the middle of 2027, although higher demand could bring that forward.

Pfizer told Reuters the decision followed an internal review and did not result from a new safety, effectiveness or quality concern. In the manufacturer’s filings with Health Product Shortages Canada, Pfizer gave business reasons for the discontinuations.

The cream has been discontinued; tablets are still in the supply chain

The manufacturer’s report for Premarin vaginal cream lists Nov. 3 as the actual discontinuation date. The cream had already been in shortage since June. Pfizer’s separate reports for the 0.3 mg, 0.625 mg and 1.25 mg oral tablets all list June 30, 2027, as the anticipated discontinuation date. That date is a forecast; the stock remaining at any one pharmacy may differ.

The affected products contain conjugated estrogens. The vaginal cream is a local treatment, while the oral products are systemic hormone therapy. Pfizer told Reuters that the decision did not extend to the hospital-use intravenous Premarin formulation.

Patch shortages and a separate intravenous Premarin interruption

Health Canada identifies supply constraints involving some strengths of Bayer’s Climara and Sandoz’s Estalis, Estradot and Estradiol Derm patches. It attributes the interruptions to global demand and manufacturing pressures. The notice does not describe every patch strength as unavailable.

The notice also reports an anticipated shortage of intravenous Premarin from December 2026 through May 2027 because of a manufacturing disruption. The IV product treats abnormal uterine bleeding associated with hormonal imbalance; it is not indicated for menopausal hormone therapy. This is separate from Pfizer’s cream and tablet discontinuations.

Selected estrogen products marketed in Canada

CPhA identifies the following selected estrogen products in its shortage resource. All contain 17-beta estradiol. Their formulation, strength and DIN are listed below to distinguish the products considered when assessing alternatives.

CPhA Table 1: Estrogen products by formulation
ProductStrengthDIN
Patches
ClimaraBayer Incorporated25 mcg02247499
50 mcg02231509
75 mcg02247500
Estradiol DermSandoz Canada Inc.50 mcg02246967
75 mcg02246968
100 mcg02246969
EstradotSandoz Canada Inc.25 mcg02245676
37.5 mcg02243999
50 mcg02244000
75 mcg02244001
100 mcg02244002
Gels
DivigelSearchlight Pharma Inc.0.1%02424835
02424843
02424924
EstrogelOrganon Canada Incorporated0.06%02238704
Oral tablets
Lupin-EstradiolLupin Pharma Canada Limited0.5 mg02449048
1 mg02449056
2 mg02449064

Source: Canadian Pharmacists Association, Menopausal Hormone Therapy Shortage, November 2026, Table 1, page 1. Strengths, doses and adverse effects are those listed by CPhA.

Marketed status does not confirm local stock, insurance coverage or suitability for a particular patient. The products are not a list of universally interchangeable replacements for Premarin.

Combined and vaginal products are listed separately

CPhA’s second table covers combined estrogen/progestin products: Activelle LD, Activelle, Angeliq, Bijuva and Estalis.

For vaginal treatment, CPhA lists Estragyn vaginal cream, Estring, Imvexxy and Vagifem 10. Those options are presented separately from systemic therapies. The resource says vaginal estrogen can be used on its own for genitourinary syndrome of menopause or added when vaginal symptoms persist despite systemic treatment.

The product tables identify strengths, drug identification numbers and manufacturers. They are lists of selected marketed products, rather than a guarantee that each product is in stock at a particular pharmacy. CPhA directs readers to Health Product Shortages Canada for changing supply and discontinuation information.

Switching requires reassessment, monitoring and appropriate uterine protection

CPhA describes its document as support for clinicians managing shortages among patients already receiving treatment. It is not a comprehensive clinical practice guideline. The association says professional assessment and judgment remain necessary when selecting an alternative.

The resource identifies cost, adherence and patient preference as factors in choosing another hormonal treatment. It refers to the Canadian Menopause Society’s systemic hormone-therapy equivalency table as a general guide and calls for monitoring effectiveness and safety after a switch, with dose adjustments where needed.

It specifically addresses patients with an intact uterus moving from a combined systemic estrogen/progestogen product to systemic estrogen alone: a progestogen should be added to reduce the risk of endometrial hyperplasia. The document also discusses potential advantages of transdermal estrogen, including a potentially lower venous-thromboembolism risk than oral treatment in selected patients.

CPhA describes MHT as the most effective treatment for vasomotor symptoms in patients younger than 60 and less than 10 years past menopause who have no MHT contraindications. Its discussion does not present every formulation as suitable for every patient.

Table 5: Nonhormonal options for menopausal symptoms

CPhA discusses nonhormonal medicines for vasomotor symptoms when MHT is undesirable or contraindicated. Its listed doses and adverse effects are set out below to support professional assessment during a shortage.

CPhA Table 5: Nonhormonal medicines for menopausal symptoms
MedicineDoseAdverse effects
Alpha-2 adrenergic agonist
Clonidine0.05 mgOral
Twice daily
Dizziness, dry mouth, drowsiness and constipation.
Anticholinergic agents
Oxybutynin2.5–5 mgOral
Twice daily
Dry mouth, constipation and tachycardia.
Oxybutynin, extended release15 mgOral
Daily
Dry mouth, constipation and tachycardia.
Gamma-aminobutyric acid derivatives
Gabapentin300 mgOral
Three times daily
Somnolence and dizziness.
Pregabalin150–300 mgOral
Daily total
Somnolence and dizziness.
Neurokinin receptor antagonists
Elinzanetant120 mgOral
At bedtime
Headache, abdominal pain, diarrhea, nausea, dizziness, fatigue and seizure risk.
Fezolinetant45 mgOral
Daily
Abdominal pain, diarrhea, insomnia, back pain and elevated liver-function tests.
Selective serotonin reuptake inhibitors
Citalopram10–20 mgOral
Daily
Gastrointestinal upset, sexual dysfunction and weight gain.
Escitalopram10–20 mgOral
Daily
Gastrointestinal upset, sexual dysfunction and weight gain.
Paroxetine10–20 mgOral
Daily
Gastrointestinal upset, sexual dysfunction and weight gain.
Serotonin–norepinephrine reuptake inhibitors
Desvenlafaxine50–100 mgOral
Daily
Gastrointestinal upset, dry mouth, drowsiness, nervousness and sexual dysfunction.
Venlafaxine37.5–75 mgOral
Daily
Gastrointestinal upset, dry mouth, drowsiness, nervousness and sexual dysfunction.

Source: Canadian Pharmacists Association, Menopausal Hormone Therapy Shortage, November 2026, Table 5, page 4. Strengths, doses and adverse effects are those listed by CPhA.

Table 6: Nonestrogen options for genitourinary symptoms

The resource lists the following nonestrogen therapies for genitourinary syndrome of menopause, including vaginal dryness and dyspareunia.

CPhA Table 6: Nonestrogen therapies for genitourinary symptoms
TreatmentDose / useAdverse effects
Ospemifene oral tablet60 mg1 tablet, oral
Daily
Hot flashes, vaginal discharge, muscle spasms and excessive sweating.
Prasterone vaginal ovule6.5 mg1 ovule, vaginal
Daily
Vaginal discharge.
Vaginal lubricantsAs neededNone listed in the CPhA table.
Vaginal moisturizersRegular useFor example
2–3 times weekly
None listed in the CPhA table.

Source: Canadian Pharmacists Association, Menopausal Hormone Therapy Shortage, November 2026, Table 6, page 5. Strengths, doses and adverse effects are those listed by CPhA.

CPhA lists conjugated estrogen/bazedoxifene and tibolone in a separate table of alternative hormonal products.

The document also notes uses of estrogen outside menopause care, including off-label feminizing hormone therapy for transgender and gender-diverse patients and add-back treatment during GnRH-agonist therapy. These uses are distinguished from the approved indications described in the resource.

CPhA asks health-care providers to help patients confirm that an alternative is covered under the applicable provincial formulary or private plan. Selection of another marketed product does not establish equivalent insurance coverage.

Health Canada continues supply monitoring

Health Canada says the resource’s alternatives are currently available without reported shortages. It is working with manufacturers, governments and other stakeholders and advises patients to discuss options with a doctor or pharmacist. The department also cautions against unlicensed sellers and unauthorized products.

Pfizer’s manufacturer reports remain the source for changes to the expected end of tablet supply. CPhA’s resource provides treatment options; it does not reverse the Premarin discontinuations.

References

  1. Pfizer confirmation of Canadian Premarin discontinuations — Reuters, Original company confirmation, Nov. 12, 2026
  2. Premarin vaginal cream discontinuation report — Pfizer Canada / Health Product Shortages Canada, Actual discontinuation Nov. 3, 2026
  3. Premarin 0.3 mg tablet discontinuation report — Pfizer Canada / Health Product Shortages Canada, Anticipated discontinuation June 30, 2027
  4. Premarin 0.625 mg tablet discontinuation report — Pfizer Canada / Health Product Shortages Canada, Anticipated discontinuation June 30, 2027
  5. Premarin 1.25 mg tablet discontinuation report — Pfizer Canada / Health Product Shortages Canada, Anticipated discontinuation June 30, 2027
  6. Menopause Hormone Therapy – Estradiol Transdermal Patches and Conjugated Estrogen Drugs in short supply in Canada: Notice — Health Canada, Notice dated November 19, 2026
  7. Menopausal Hormone Therapy Shortage — Canadian Pharmacists Association, November 2026 edition; accessed November 19, 2026

Discussion

0 comments

Join the discussion. Anyone can read the comments. To comment, log in or create a free individual account.

No comments yet.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.